The James T. Lubin Clinician Scientist Fellowship Award supports the post-residency training of clinicians who are committed to careers in academic medicine with a specialization in rare neuro-immune disorders of the CNS (including TM, AFM, ADEM, NMOSD, and ON) clinical care and research. The intent of this program is to support up to two years of clinical care and research training at one of four institutions listed below that specialize in treating individuals with these disorders. It is expected that upon completion of the program, participants will be committed to a combined clinical and research career and will be prepared to direct robust clinical and research programs relevant to TM, AFM, ADEM, NMOSD, and ON in their clinical department.

More about the Transverse Myelitis Association, our mission and goals can be found on our website http://myelitis.org.

OBJECTIVES

After completing the fellowship program, the Fellows will have acquired independent research and clinical skills and gained experience necessary to develop into clinician-scientists who:

- Provide high quality, state-of-the-art, comprehensive clinical care to patients with TM (including AFM), ADEM, NMOSD, ON and other rare neuro-immune disorders
- Advance the research and understanding of these disorders through clinical research and/or basic science research
- Become an active participant and future leader in the rare neuro-immune disorders clinical community

2018-2020 FELLOWSHIP APPLICATION

Open Date – July 5, 2017
Due Date – August 30, 2017
Review and Board approval – October 2017
Awards announced – November 2017
AWARD NUMBER AND FUNDS

The number of the James T. Lubin Clinician Scientist Fellowships awarded will be based on the availability of funds to support this program.

The objective is to provide salary (based on PGY5 for adult neurologists and PGY6 for pediatric neurologists) and benefits, and research support for up to 2 years of post-doctoral training to ensure a future of well-trained clinician-scientists focused on rare neuro-immune disorders. The total salary and benefits requested must be based on a full-time, 12-month staff appointment. The maximum allowed support through the Fellowship is $80,000 per year. The Fellow should be at least 80% funded through The TMA and no more than $20,000 can be used for non-salary support activities. Acceptable support activities include tuition and fees related to career development, research expenses, such as supplies, equipment and technical personnel and travel to research meetings or training. The TMA will also consider international candidates who fulfill criteria for clinical training activities in the USA and plan to return to their countries of origin to establish clinical activities focused on rare neuro-immune disorders.

Indirect Costs (also known as Facilities & Administrative [F&A] Costs) are not reimbursed by The TMA.

ELIGIBILITY AND ADDITIONAL GUIDELINES

- Applicants must have a health professional doctoral degree to be eligible to apply and must have completed their clinical training, including specialty and, if applicable, subspecialty training prior to receiving the Fellowship Award
- Applicants must identify a mentor at one of the four institutions as listed below
- Applicant must provide a research project consistent with the research and training plan that not only demonstrates the applicant’s strengths, but also helps advance the field forward
- If accepted, Fellow must agree to participate in TMA programs, which include the Annual Quality of Life Camp, the Rare Neuro-Immune Disorder Symposium, The TMA Ask the Expert Podcast Series, and The TMA publications
CURRENTLY PARTICIPATING INSTITUTIONS AND MENTORS

Institution: Johns Hopkins Transverse Myelitis Center, Baltimore, MD

Mentor: Carlos Pardo-Villamizar, MD, Associate Professor of Neurology (Division of Neuroimmunology and Neuroinfectious Disorders) and Pathology (Neuropathology) at Johns Hopkins University School of Medicine in Baltimore, Maryland.

Bio: Dr. Pardo is an Associate Professor of Neurology (Division of Neuroimmunology and Neuroinfectious Disorders) and Pathology (Neuropathology) at Johns Hopkins University School of Medicine in Baltimore, Maryland. His clinical specialization is on neuroimmunological and Infectious disorders of the nervous system, with particular focus on multiple sclerosis, transverse myelitis, neurosarcoidosis, and neurological complications of autoimmune disorders. Dr. Pardo is the Director of the Johns Hopkins TM Center, the first clinical center focused on clinical and research studies of myelitis and myelopathies established in the US. He is the principal investigator of the Neuroimmunopathology Laboratory, member of the HIV Neurosciences Research Group and clinical neurologist at the Multiple Sclerosis and Transverse Myelitis Centers at Johns Hopkins Hospital. His laboratory focuses on immunopathology studies of neurological disorders, biomarkers and pathogen discovery in brain and cerebrospinal fluid. He collaborates closely with the intramural branch of the NINDS in projects of clinical-neuroimaging and pathology correlation in neuroimmunological disorders and is part of the collaborative efforts in projects of pathogen discovery in brain disorders and brain microbiome research.

Contact: cpardov1@jhmi.edu

Website: Click here

Institution: University of Texas Southwestern Medical Center, Dallas, TX

Mentor: Benjamin Greenberg, MD, MHS, Associate Professor at UT Southwestern Medical Center. Director of the Transverse Myelitis and Neuromyelitis Optica Program, Dallas, TX,
Dr. Benjamin Greenberg received his Bachelor of Arts degree from Johns Hopkins University and his Masters Degree in Molecular Microbiology and Immunology from the Johns Hopkins School of Public Health in Baltimore, Maryland. He attended medical school at Baylor College of Medicine in Houston, Texas. Then, he completed an internship in medicine at Rush Presbyterian-St. Lukes Medical Center in Chicago, Illinois before going on to his residency in neurology at The Johns Hopkins Hospital in Baltimore, MD. He then joined the faculty within the division of neuroimmunology at Hopkins and became the Co-Director of the Transverse Myelitis Center and Director of the Encephalitis Center. In January of 2009 he was recruited to the faculty at the University of Texas Southwestern Medical Center where he was named Director of the new Transverse Myelitis and Neuromyelitis Optica Program. That same year he established the Pediatric Demyelinating Disease Program at Children’s Medical Center Dallas. He serves as the Director of the Neurosciences Clinical Research Center. Dr. Greenberg is recognized internationally as an expert in rare autoimmune disorders of the central nervous system (e.g., transverse myelitis, neuromyelitis optica spectrum disorder, ADEM and autoimmune encephalitis). He splits his clinical time between seeing both adult and pediatric patients. He routinely consults on the inpatient units of Clements University Hospital, Zale Lipshy, Parkland and Childrens Medical. His research interests are in both the diagnosis and treatment of transverse myelitis, neuromyelitis optica spectrum disorders, encephalitis, multiple sclerosis and infections of the nervous system. He is actively involved in developing better ways to diagnose and prognosticate for patients with these disorders. He has led an effort to improve biorepository development and has created uniform protocols for sample handling and analysis. As part of this initiative, his research has identified novel biomarkers that may be able to distinguish between patients with various neurologic disorders. He also coordinates trials that study new treatments to prevent neurologic damage and restore function to those who have already been affected.

Contact: benjamin.greenberg@utsouthwestern.edu

Website: Click here
Institution: The Children's Hospital of Philadelphia, Philadelphia, PA

Mentor: Brenda Banwell, MD, Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Bio: Dr. Banwell graduated with a degree in medicine from The University of Western Ontario in 1991. She pursued a residency in pediatrics at The Hospital of Western Ontario, University of Western Ontario, from 1991-1994 and a pediatric neurology residency at The Hospital for Sick Children, University of Toronto from 1994-1997. Dr. Banwell then spent two years completing a neuromuscular disease fellowship at the Mayo Clinic, Rochester, Minnesota. In 1999, Dr. Banwell was appointed as an assistant professor of pediatrics (neurology) at the Hospital for Sick Children and University of Toronto. She was promoted to associate professor in 2006 and full professor in 2012. As of July 1, 2012, Dr. Banwell has taken on the role of chief of neurology at The Children's Hospital of Philadelphia. Dr. Banwell's clinical and research interests are in pediatric multiple sclerosis and other inflammatory brain disorders. Dr. Banwell is the lead Investigator of a 24 site study of acquired demyelination in children, a study that has been continuously funded since 2004. The Canadian Pediatric Demyelinating Disease study now partners with the Children's Hospital of Philadelphia, and has collaborative research projects with the US Network of MS Centers. A comprehensive clinical, biospecimen, and research-quality MRI database has been established, serving as a core resource to evaluate biomarkers, as well as clinical-radiographic features of TM, ON, ADEM, NMOSD and MS in children. The Demyelinating Disease Program at CHOP is fully integrated with the MS program at the Hospital of the University of Pennsylvania to create an age-span program for demyelinating disorders, and was recently recognized as a National MS Center of Excellence. The program has a National MS Society funded MS Fellowship program with a well-organized educational mandate.

Contact: BanwellB@email.chop.edu

Website: Click here
Institution: University of Utah, Salt Lake City, Utah

Mentor: Stacey L. Clardy, MD, PhD, Assistant Professor of Neurology, Division of Neuroimmunology, University of Utah, and Director of Autoimmune Neurology Fellowship

Bio: Dr. Clardy is both clinical and research faculty in the Division of Neuroimmunology within the Department of Neurology. Prior to joining the University of Utah team Dr. Clardy furthered her training with a fellowship in Autoimmune Neurology at the Mayo Clinic. Her training and experience focus on the evaluation and management of autoimmune and paraneoplastic disorders of the nervous system. The spectrum of autoimmune and paraneoplastic neurological disorders intersects all traditional neurology subspecialties, including movement disorders, epilepsy, behavioral/cognitive, neuromuscular, autonomic, demyelinating, and neurooncologic. Her main clinical interest is devoted to patients affected by antibody-mediated disorders of the nervous system, as well as demyelinating CNS disease, including neuromyelitis optica (NMO) and multiple sclerosis, and Central nervous system complications of rheumatologic disease. She established the Autoimmune Neurology Clinic at the University of Utah, one of the few clinics in the United States focused on serving this group of patients. Dr. Clardy is also the Director of the Autoimmune Neurology Fellowship program.

Contact: stacey.clardy@hsc.utah.edu

Website: Click here
2018 APPLICATION INSTRUCTIONS

- **DO NOT FILL OUT THIS PAPER FORM.** Please fill out the application online at [https://thetma.wufoo.com/forms/20182020-james-t-lubin-fellowship-application/](https://thetma.wufoo.com/forms/20182020-james-t-lubin-fellowship-application/). This document is meant to serve as a reference for you before you fill out the online form.

- The deadline for receipt of a completed application is August 30, 2017 for the award to become effective July 1, 2018. Exceptions to the start date should be discussed with The TMA.

- For any text attachments for the online application form, use standard size black type no smaller than 11 point; do not use photo reduction.

- Copies of any preprints, reprints, or other additional materials must be submitted with the application.

- The application must be submitted accompanied by all supporting documents. Please do not submit your application until you have assembled all references, transcripts and other requested materials.

- The application cannot be considered for review unless signed by the applicant and the mentor. “Per” signatures will be disallowed.

- The application and all correspondence relating to it must be received at The TMA by August 30, 2017 to be considered for a fellowship to begin July 1, 2018.

- For more about the goals of the Fellowship, please visit – [https://myelitis.org/shaping-the-future/our-programs/james-t-lubin-fellowship](https://myelitis.org/shaping-the-future/our-programs/james-t-lubin-fellowship)

- If you have any questions about the preparation of your application, please contact Gabrielle deFiebre at gdefiebre@myelitis.org.
I. APPLICANT

FIRST ___________________ MIDDLE ___________________ LAST ___________________

DEGREES ________________________________________________________________

STREET ________________________________________________________________

CITY _______________ STATE ________ ZIP CODE ________________

TEL. _______________ FAX ________________

EMAIL ADDRESS _______________________________________________________

II. INSTITUTION’S FINANCIAL OFFICER

NAME ________________________________________________________________

POSITION _____________________________________________________________

DEPARTMENT __________________________________________________________

STREET ________________________________________________________________

CITY _______________ STATE ________ ZIP CODE ________________

TEL. _______________ FAX ________________

EMAIL ADDRESS _______________________________________________________

III. PAYMENT INFORMATION

Award Checks Payable To: ________________________________________________

IV. BUDGET

Please attach a budget using your institution’s acceptable format. The fellowship award is payable to the institution on a quarterly basis to cover allowable costs as above through a grant agreement. Please refer to The TMA’s Guidelines for Funding and Public Access Policy for information concerning allowable expenses and other instructions concerning the preparation of your budget. No indirect costs or other institutional taxes will be covered by the fellowship per the policies and practices of The TMA. A letter must be attached from the mentor’s institution confirming that the institution has committed to supporting the remaining costs for the fellow candidate, including but not limited to the cost for malpractice insurance, any salary augmentation and a benefits package. These itemized costs should be disclosed in the letter.
V. BIOGRAPHICAL SKETCH OF APPLICANT

Please attach your biographical sketch in NIH format (include Education, Academic Honors, Professional Experience, Membership in Professional Organizations, Bibliographic citations).

VI. PERSONAL STATEMENT

Describe your long and short-term career goals. Discuss how the fellowship will advance these goals. Be sure to address how your career goals relate to clinical care and research in the rare neuro-immune disorders. Describe your personal qualifications for this award. (Please limit to one page).

VII. CLINICAL TRAINING PLAN

Using the following outline, describe the training plan that you and your mentor have developed to meet the required components of training. Please limit to two pages.

Components of Training:

1. Direct, supervised ADEM, NMOSD, ON and TM patient care (60%)
2. Exposure to multidisciplinary care (20%)
3. Didactic activities (10% - incl. producing a clinical paper, attending lectures, grand rounds, etc.)
4. Other (10%) please specify:

VIII. RESEARCH TRAINING PLAN

Describe the training plan that you and your mentor have developed to meet the required components of training. Please limit to two pages.

IX. RESEARCH PROJECT INFORMATION

PROJECT START DATE

PROJECT END DATE

Please check all categories that apply to your proposal:

- [ ] HUMAN SUBJECTS
- [ ] HUMAN TISSUES
- [ ] HUMAN CELL LINES
- [ ] HUMAN FETAL TISSUE / STEM CELLS

Has this project been submitted to or will it be submitted to another agency?

- [ ] YES
- [ ] NO

If you answered yes, please identify the name of the agency:
X. HUMAN SUBJECTS AND/OR VERTEBRATE ANIMALS

The applicant institution has the primary responsibility for protecting the rights and welfare of human subjects and for ensuring the humane care and use of animals in all research activities supported by The Transverse Myelitis Association and of informing The TMA of all relevant assurances and certifications. If an award is made as a result of this application, it is the responsibility of the grantee or fellow and the Institution to inform The TMA within a reasonable time of any change in the research protocol.

By virtue of the signature of an official authorized to sign for the institution on this application, the institution is declaring that all applicable Federal, State and Local regulations will be followed during the tenure of any grant awarded as a result of this Application. This form must be completed and submitted with any application to The TMA for the support of research or training. In addition, a copy of the approval letters signed by the Chairperson of the Institutional Review Board (IRB) and/or the Institutional Animal Use and Care Committee, as appropriate, must accompany any application.

I. Human Subjects
Will Human Subjects be Used:

☐ YES
☐ NO

IRB approval must be obtained and evidence of approval submitted as part of the PDF file that is uploaded in the Letters section, where applicable and approved. For applications that have not been submitted yet or are pending review, approval letters must be submitted within 90 days of grant start date.

IRB APPROVAL

IF EXEMPT, PROVIDE REASON

APPROVAL DATE             EXPIRATION DATE

IRB PROTOCOL NUMBER

The Assurance of Compliance Number issued to the applicant institution by the Federal Office of Protection from Research Risks: xc549863

ASSURANCE OF COMPLIANCE NUMBER
ii. Vertebrate Animals

Will Vertebrate Animals be Used:

☐ YES
☐ NO

Institutional approval must be obtained and evidence of approval submitted as part of the PDF file that is uploaded in the Letters section, where applicable and approved. For applications that have not been submitted yet or are pending review, approval letters must be submitted within 90 days of grant start date.

Institutional Animal Care and Use Committee Approval:

<table>
<thead>
<tr>
<th>APPROVAL DATE</th>
<th>EXPIRATION DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APPROVAL NUMBER

ANIMAL WELFARE ASSURANCE NUMBER

XI. LAY LANGUAGE SUMMARY OF PROPOSED PROJECT

Please provide a summary of your proposed research in language suitable for a news release to the lay public. Please limit your summary to 500 words or less.

XII. SCIENTIFIC SUMMARY OF PROPOSED PROJECT

Please provide a summary of the proposed research. Please limit your summary to 500 words or less. Be certain to address the relevance of the project to ADEM, NMOSD, ON and/or TM.

XVIII. REFERENCE LETTERS

One of the letters of support must be from the mentor or authorized official of the sponsoring institution acknowledging support for employment of the individual for 2 years, for additional salary support to the individual as necessary, the commitment to protect at least 70% of the candidate's time for clinical care/clinical research/basic science research of rare neuro-immune disorders (general neurology clinic or inpatient service are excluded from the 70% commitment), and support for the applicant covering additional costs, such as for malpractice insurance and fringe benefits.
The letter must also address each of the following issues:

1. What makes the applicant an ideal candidate for this competitive fellowship,
2. How the fellowship fits into the long-term goals of having the candidate become a future leader in the field of neuro-immune diseases, such as TM, NMOSD and ADEM,
3. Why the fellowship is important for the applicant at this point in their career.

Instructions: Provide three reference letters from people, including your mentor.

SUMMARY OF MATERIALS TO BE SUBMITTED WITH THE APPLICATION

- Three Reference Letters
- Proposed Budget
- Approval Letters for use of human subjects and/or animals
- Medical School Transcripts (Scanned originals or photocopies are acceptable)
- Applicant’s Biosketch
- Personal Statement
- Clinical Training Plan
- Research Training Plan
- Lay Language Summary of Research Project
- Scientific Summary of Research Project
Applicant’s full name and Degree(s)

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
<th>Date</th>
<th>Office Telephone No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mentor:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial Officer:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Official Authorized to Sign for Institution [include official’s title]:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>